tuesday decemb 13 1994 part ii depart health human servic food drug administr 21 cfr part 201 specif requir content format label human prescript drug revis pediatr use subsect label final rule feder regist vol 59 238 tuesday decemb 13 1994 rule regul usdept depart health human servic usdept usbureau food drug administr usbureau cfrno 21 cfr part 201 cfrno rindock docket 92n0165 rindock specif requir content format label human prescript drug revis pediatr use subsect label agenc agenc food drug administr hh agenc action action final rule action summari summari food drug administr fda amend regul govern content format label human prescript drug product final rule revis current pediatr use subsect profession label requir prescript drug provid inclus complet inform use drug pediatr popul age birth 16 year final rule appli prescript drug product includ biolog prescript drug product recogn sever method establish substanti evid support pediatr label claim includ reli certain case studi carri adult final rule also requir substanti evid support pediatr use use particular pediatr popul label shall state sponsor must reexamin exist data determin whether pediatr use subsect label modifi base adequ well control studi adult inform support pediatr use appropri submit supplement applic compli new 201 57 f 9 iv decemb 13 1996 action respond concern fda elsewher current prescript drug label often contain adequ inform use drug pediatr popul action promot safer effect use prescript drug pediatr popul summari date date effect januari 12 1995 agenc accept pediatr use inform base revis 201 57 f 9 21 cfr 201 57 f 9 januari 12 1995 sponsor must reexamin exist data appropri submit supplement applic compli new 201 57 f 9 iv decemb 13 1996 date inform contact erica l key center drug evalu research hfd362 food drug administr 7500 standish pl rockvil md 20855 3015941046 supplem supplementari inform background feder regist octob 16 1992 57 fr 47423 fda propos amend regul pertain content format prescript drug label 201 57 revis current pediatr use subsect 201 57 f 9 allow broader basi inclus inform use drug pediatr popul propos would allow pediatr claim base adequ well control studi pediatr popul also case trial adult propos regul describ data need pediatr claim base trial adult indic specif label languag locat variou kind inform fda issu current pediatr label requir 1979 44 fr 37434 june 26 1979 current regul codifi 201 57 f 9 requir specif pediatr indic describ indic usag section label appropri pediatr dosag provid dosag administr section current regul also requir recommend pediatr use base substanti evid deriv adequ well control studi pediatr popul unless requir waiv drug safeti effect pediatr popul cannot establish drug use pediatr popul associ specif hazard current regul requir appropri statement detail establish pediatr use subsect describ content format 1979 regul intend encourag drug label would regularli provid adequ inform use prescript drug pediatr patient state preambl propos rule final rule base howev prescript drug product still lack adequ inform use pediatr popul exampl inform survey done 1990 american academi pediatr examin label new molecular entiti approv 1984 1989 found 80 percent inform pediatr use survey shown label mani prescript drug state safeti effect children establish contain inform pediatr use even drug commonli prescrib pediatr patient fda continu concern without adequ inform practition may reluct prescrib certain drug pediatr patient may prescrib inappropri choos dosag instanc arbitrarili base child age bodi weight bodi surfac area without specif inform whether appropri result pediatr patient may expos increas risk advers reaction decreas effect drug prescrib may deni access valuabl therapeut agent continu absenc pediatr use inform prescript drug label may due part impress perhap convey exist regul pediatr claim must alway base adequ well control studi conduct pediatr popul given mani problem associ test drug pediatr popul e g obtain inform consent test directli benefit child use placebo control vulner popul studi meet standard often difficult obtain exist fda regul fact requir control trial alway conduct pediatr popul support pediatr use current 201 57 f 9 need studi may waiv data satisfi requir law basi grant waiver howev clear exist regul section 201 57 f 9 iv final rule clarifi agenc determin data adequ well control studi adult subject provid substanti evid effect pediatr popul summari rule intend provid practition pediatr use inform label human prescript drug product practition reliabl inform upon base decis prescrib drug use pediatr patient rule encourag manufactur provid inform drug label upon practition base decis rule howev limit manner practition may prescrib approv drug ii highlight final rule final rule revis current pediatr use subsect profession label requir prescript drug provid inclus comprehens inform use drug pediatr popul final rule product may label pediatr use base adequ well control studi adult togeth inform support pediatr use e g pharmacokinet data safeti data pharmacodynam data relianc studi adult possibl waiver provis exist rule waiver provis often use cours product may also label pediatr use base adequ well control studi pediatr popul pediatr age group birth 16 year includ pediatr age group often call neonat infant children adolesc final rule term children interpret refer particular subset pediatr popul age 2 12 year make clear provis rule appli entir pediatr popul refer children propos rule delet replac pediatr popul pediatr patient major provis final rule summar follow final rule continu permit specif pediatr indic e indic differ approv adult support adequ well control studi appropri pediatr popul describ indic usag section label appropri pediatr dosag given dosag administr section label pediatr use subsect label must includ limit pediatr indic need specif monitor specif hazard drug differ pediatr adult respons drug inform relat safe effect use drug pediatr patient specif statement pediatr use drug indic also approv adult base adequ well control studi pediatr popul must summar pediatr use subsect label discuss detail appropri clinic pharmacolog clinic studi section appropri pediatr dosag must given dosag administr section label subsect label must also cite limit pediatr use statement need specif monitor specif hazard associ use drug subset pediatr popul e g neonat differ pediatr adult respons drug inform relat safe effect pediatr use drug pediatr use statement may also base adequ well control studi adult provid agenc conclud cours diseas drug effect suffici similar pediatr adult popul permit extrapol adult efficaci data pediatr patient need pharmacokinet data allow determin appropri pediatr dosag addit pediatr safeti inform must also submit requir find substanti evid support specif pediatr indic pediatr use statement met particular pediatr subgroup pediatr use subsect label must contain statement appropri character limit safeti effect pediatr patient age _ year month week establish use drug associ specif hazard pediatr subgroup pediatr use subsect must contain inform hazard appropri refer complet descript hazard contraind warn section label requir find substanti evid support pediatr indic pediatr use statement met pediatr popul pediatr use subsect label must contain follow statement safeti effect pediatr patient establish use drug prematur neonat infant pediatr subgroup associ specif hazard pediatr use subsect must contain inform hazard appropri refer complet descript hazard contraind warn section label sponsor believ pediatr use subsect appropri relev label particular drug product must provid fda reason justifi omiss may propos altern statement final recogn hazard inact ingredi pose pediatr popul final rule requir prescript drug label contain statement inact ingredi might toxic neonat pediatr subgroup iii gener comment propos rule fda receiv 11 comment propos rule prescript drug manufactur prescrib profession societi organ special interest pediatr popul lay public other support propos label chang call time import import step facilit inclus inform use drug children approv label signific step toward goal includ infant children drug approv process way fill gap inform current exist area appropri drug usag children one comment exampl state provid pediatr use inform label help health profession reach ration drug therapi decis pediatr patient comment ad inform use pharmacist assur ration drug therapi special popul posit addit drug inform label enhanc likelihood posit outcom pediatr patient howev comment less support includ one state commend fda initi improv inform avail physician pediatr patient regard prescript drug use remain concern approach measur assist physician comment also rais specif issu consider agenc issu describ definit pediatr 1 sever comment suggest age breakdown within pediatr popul might appropri pediatr age rang begin birth may cover individu old 18 year 21 year encompass subspecialti neonatolog adolesc medicin one comment suggest rule defin pediatr children 12 year commonli accept age 12 year 18 year may includ without previou clinic work age group comment also suggest rule state age group pharmacokinet studi done order extrapol result infanc adolesc state whether age rang broken subgroup test requir anoth comment said definit pediatr would consid drug metabol pharmacokinet interact variou organ bodi system comment suggest system distinct class drug consid differ may logic appropri anoth comment note pediatr patient homogen age group show signific differ function physiolog function comment suggest inform clinic studi subdivid age group respect respons drug suggest age categori prematur infant newborn children 2 year age children 2 year 13 year adolesc 13 year 18 year anoth comment said individu 16 year 18 year age pose particular problem suggest consult american academi pediatr committe drug consid defin age categori group pediatr label pediatr use subsect label inform use drug pediatr patient locat 201 57 f 9 describ gener term kind inform includ pediatr use subsect attempt resolv mani difficult issu relat use drug popul appear subsect e g age group cover depend data avail abil defin result specif subgroup gener matter howev agenc offer follow guidanc use breakdown follow age categori pediatr popul commonli distinguish although distinct inevit arbitrari 1 birth 1 month neonat 2 1 month 2 year age infant 3 2 year 12 year children 4 12 year 16 year adolesc possibl data analyz group usual necessari establish drug product effect group may hand import pharmacokinet inform group especi younger age group guid dose addit inform specif studi neonat establish safeti although agenc determin term pediatr patient refer individu birth 16 year age agenc recogn drug adult studi may applic pediatr patient age 16 year pass puberti inde primari purpos rule allow pediatr label base adult studi appropri although mani case addit pharmacokinet safeti data may need support pediatr use statement case particularli pediatr patient 12 16 year age group may less addit data need b applic rule biolog drug product 2 one comment said unclear whether rule appli biolog drug product rule well 201 57 gener appli biolog drug product c pediatr studi 3 one comment note 80 percent drug label current contain languag exclud use drug pediatr patient limit use specif age group comment ask fda encourag sponsor includ pediatr patient clinic studi drug like effect indic popul state preambl propos rule fda encourag sponsor includ pediatr patient clinic studi analyz investig new drug applic new drug applic nda determin whether studi popul done drug approv 57 fr 47423 47424 certain circumst agenc may requir clinic studi pediatr popul conduct market approv see respons comment number 4 section iii c document drug like effect pediatr use agenc make clear label pediatr use may sometim base adequ well control studi adult addit pediatr data fda intend rule call attent need creat review data pediatr use 4 one comment ask whether fda intend requir sponsor submit inform specif pediatr indic use avail data suggest indic use would permit regul comment said may good reason sponsor might wish seek pediatr indic use drug even avail evid would support use exampl drug benefit risk ratio pediatr popul might differ adult might suffici better altern therapi avail pediatr use addit comment express concern drug test adult may provid suffici legal defens claim injuri child comment said sponsor forc assum place posit defend action unless sponsor believ data support pediatr use suffici sponsor mandat forc rule seek pediatr use sponsor whatev reason wish anoth comment express concern fda might delay approv product good exist avail data safeti efficaci adult accept pediatr inform develop rule add new requir sponsor carri new pediatr studi requir sponsor submit label claim inadequ support new 201 57 f 9 iv provid pediatr use statement may base adequ well control studi adult provid cours diseas drug effect suffici similar pediatr adult popul permit extrapol adult efficaci data pediatr patient sponsor requir reexamin exist data determin whether pediatr use subsect label modifi base adequ well control studi adult inform support pediatr use safeti effect pediatr use demonstr submit supplement applic compli new 201 57 f 9 iv decemb 13 1996 sponsor believ diseas drug effect similar pediatr adult popul believ use pediatr patient otherwis adequ support data propos revis label provis new 201 57 f 9 vi sponsor may propos label state safeti effect pediatr patient establish addit new 201 57 f 9 vii sponsor believ none statement describ paragraph f 9 ii f 9 vi section appropri relev label particular drug sponsor must provid reason omiss statement may propos altern statement respons propos fda may permit use altern statement fda determin statement describ paragraph appropri relev drug label altern statement accur appropri section 201 57 f 9 vii modifi make explicit although rule add new requir conduct pediatr studi variou provis feder food drug cosmet act act public health servic act ph act exist regul author fda requir studi certain circumst section 505 k act 21 u c 355 k fda may requir nda holder establish record submit report agenc data relat clinic experi data inform order determin whether may ground revok nda approv requir may establish either regul order regard nda 21 u c 355 k 1 exist regul requir applic holder report agenc advers experi occur cours use product profession practic well clinic investig 21 cfr 312 32 314 80 addit approv applic holder must submit part annual report summari signific new inform might affect safeti effect label product well copi unpublish publish report studi drug 21 cfr 314 81 b 2 b 2 v b 2 vi report also must contain descript action compani taken intend take new inform submiss supplement addit warn initi new studi 21 cfr 314 81 b 2 section 505 e act specifi ground agenc may withdraw suspend approv nda immin hazard public health approv nda may suspend immedi secretari depart health human servic addit circumst approv nda withdrawn clinic experi data show product unsaf shown safe condit use upon basi applic approv moreov approv may withdrawn label fals mislead correct within reason time notic matter section 502 act 21 u c 352 drug consid misbrand label fals mislead section 201 n act 21 u c 321 n make clear mislead determin base represent made suggest label also failur reveal materi fact materi fact includ concern consequ may result use product label condit use customari usual condit use condit use may includ label use prescrib practition patient addit drug consid misbrand section 502 f act label fail bear adequ direct use fda regul defin adequ direct use direct lay person use drug safe purpos intend 21 cfr 201 5 intend use defin regul includ use one label 21 cfr 201 128 manufactur know drug use label use manufactur may requir provid adequ label use 21 cfr 201 128 prescript drug human use exempt requir carri adequ direct lay use certain circumst label prescript legend 21 cfr 201 100 among exempt criteria requir drug carri adequ label prescrib author approv applic intend use summari drug product misbrand intend use approv nda drug product also misbrand section 502 f 2 act label carri adequ warn unsaf use unsaf use may includ use pediatr patient use may danger health unsaf dosag method durat administr pediatr popul biolog drug product approv author section 351 ph act 42 u c 262 provis author promulg regul design ensur continu safeti puriti potenc product 42 u c 262 1 approv product licens applic pla may revok product conform applic requir regul safe effect intend use misbrand respect use 21 cfr 601 5 b 4 b 6 danger health commission may suspend product licens 21 cfr 601 6 section 351 b ph act one may fals label biolog product biolog drug product also subject applic drug provis feder food drug cosmet act previous discuss moreov agenc state applic market approv contain data reason sampl patient like given drug market 58 fr 39406 39409 juli 22 1993 conclus state explicitli guidelin need data gender appli equal age subgroup includ pediatr geriatr popul fda may refus approv applic fail contain suffici inform determin whether product safe effect use popul like receiv addit approv drug certain case e g drug wide use repres potenti hazard therapeut import pediatr patient fda may requir studi pediatr popul appropri label chang previous discuss alreadi approv drug may consid illeg market adequ inform safe effect use pediatr patient obtain includ label agenc thu expect sponsor seek supplement claim pediatr use support adequ data impli howev sponsor seek claim pediatr use benefit use outweigh risk determin whether includ pediatr use statement must base clinic data use inform vagu concern liabil 5 one comment said although desir use potenti relev data pediatr use subsect label understand data take place adequ well design control studi pediatr popul fda ultim may requir studi comment state fda requir manufactur fund research project regard drug safeti efficaci includ short term long term side effect pediatr patient fda agre clinic studi regard drug safeti effect pediatr patient desir agenc encourag studi appropri case discuss comment 4 section iii c document agenc author requir studi certain circumst case studi may requir prior approv pediatr use import adult pediatr diseas cannot consid suffici similar case control trial adult pharmacokinet data need may support valid pediatr label 6 one comment state fda consid altern rule includ formal review process collect analyz avail safeti efficaci data drug use pediatr popul market approv committe review could recommend test drug market specif pediatr safeti efficaci concern found fda believ comment misinterpret purpos rule rule describ kind data inform includ label pediatr popul gener sponsor respons collect continu basi avail data safeti efficaci propos revis label carri need studi circumst fda requir pediatr studi prior approv elicit agreement drug sponsor time market approv carri addit pediatr studi approv stimul conduct pediatr studi approv appropri fda make use stand advisori committe help decid whether pediatr studi need 7 one comment state fda revis rule specifi data must provid manufactur comment ask number pediatr patient would suffici determin differ age relat respons fda determin avail inform pediatr use avail drug includ includ epidemiolog studi fda declin accept comment suggest agenc believ specifi exact number pediatr patient studi would impract due variat pediatr popul respons differ drug particularli true given variou kind data use rule support pediatr label drug current review 8 one comment suggest drug current develop review fda given special consider avoid delay develop approv associ implement rule fda expect delay review approv result rule fda alreadi examin avail pediatr data current label regul princip chang creat revis regul abil reli studi adult support pediatr efficaci situat e supplement drug alreadi approv 9 one comment suggest fda work manufactur approv drug develop method allow manufactur updat label quick cost effect manner comment also said packag insert gener reflect current scientif literatur problem current method updat label comment said creat situat prescrib make decis treatment modal without benefit time inform fda believ chang regul need allow time updat label current regul applic propos chang approv label fda normal review supplement subject prior approv order receiv effect supplement rate prioriti standard subject perform goal set connect prescript drug user fee act 1992 10 one comment said file approv pediatr label supplement differ sponsor differ timet could mean label product consid substanti similar might silent regard pediatr usag other might detail comment suggest fda american academi pediatr committe drug could identifi therapeut class relabel first fda could review approv pediatr use label product differ compani coordin implement label chang similar agent respect effect claim pharmacokinet safeti data much inform drug specif review submit therefor agenc adopt comment suggest agenc advis howev gener class drug product involv fda examin label appli class f impact industri 11 one comment claim rule place nda holder competit disadvantag rel abbrevi new drug applic anda holder comment state rule would give nda holder burden respons pediatr studi literatur search impos similar burden respons anda holder fda disagre comment part rule direct anyon market prescript drug intend encourag inclus complet inform use drug pediatr popul hazard associ use rule permit new basi refer pediatr use impos new requir conduct studi pediatr popul extent nda holder access data avail anda holder data examin likelihood basi propos chang pediatr use subsect label agenc believ repres modest burden event see way gain pediatr inform label anda holder cannot requir examin data possess anda holder preclud provid pediatr use data expect rule data avail anda applic believ new safeti effect inform ad product label provid adequ support inform fda fda determin whether label gener list drug revis g minor editori chang 12 one comment said label revis editori natur use reformat exist pediatr use label inform conform rule made accord 314 70 21 cfr 314 70 chang describ annual report comment said would also facilit agenc process minor chang fda agre comment state preambl propos rule inor editori chang may made accord 314 70 57 fr 47423 47426 compli rule refer children pediatr use subsect insert label product alreadi market must chang appropri pediatr popul pediatr patient product biolog product chang consid minor editori chang state preambl propos rule biolog product chang submit accord procedur outlin 601 12 21 cfr 601 12 57 fr 47423 47426 h format propos label 13 one comment said impract imposs list label dosag hazard pediatr popul comment suggest placement gener label adult prescript drug state medic given pediatr patient without physician instruct comment said requir overli complic lengthi inform label would discourag prescrib need medic fda believ comment misinterpret propos rule purpos pediatr use label purpos rule encourag pediatr use inform label provid practition inform pediatr use 14 one comment said certain product e g corticosteroid class label effect agenc decid commun pediatr word address case pediatr label drug specif class label exist fda gener examin label product whole iv specif comment propos rule section 201 57 f 9 fda initi ad definit 201 57 f 9 indic paragraph f 9 ii f 9 viii term pediatr popul pediatr patient defin pediatr age group birth 16 year includ age group often call neonat infant children adolesc b propos 201 57 f 9 f 9 ii fda receiv comment provis renumb 201 57 f 9 ii f 9 iii final without chang c propos 201 57 f 9 iii propos 201 57 f 9 iii renumb 201 57 f 9 iv state part fda may approv drug pediatr use base adequ well control studi adult inform support pediatr use case agenc conclud cours diseas effect drug suffici similar children adult permit extrapol adult data children addit inform support pediatr use must includ data pharmacokinet drug children determin pediatr dosag inform data pharmacodynam studi drug children control uncontrol studi confirm safeti effect drug children pertin premarket postmarket studi experi may necessari establish applic adult data children 15 one comment said fda revis propos 201 57 f 9 iii indic pharmacokinet data mandatori situat anoth comment state pharmacokinet data may appropri way determin pediatr dose differ metabol distribut pediatr patient may support dose necessarili relat blood level comment state dose inhal product base pharmacokinet anoth comment said difficulti obtain inform consent use placebo control obtain adequ blood sampl pharmacokinet analysi pediatr patient seriou impedi perform studi necessari appropri pediatr label comment said well establish ethic structur within inform consent may obtain placebo control use pediatr popul current technolog requir small blood sampl measur compound accord comment primari impedi adequ clinic trial pediatr popul absenc regulatori mandat exist econom disincent agenc recogn pharmacokinet data import sourc inform may alway appropri method determin pediatr dose schedul may infeas unnecessari insuffici type data experi may sometim substitut pharmacokinet data data experi pediatr popul may need addit pharmacokinet data agenc modifi rule state addit inform support pediatr use must ordinarili includ data pharmacokinet drug pediatr popul determin pediatr dosag discuss respons comment 4 section iii c document rule creat new requir pediatr studi author requir pediatr studi alreadi exist situat data safe effect use pediatr patient may necessari approv continu market drug revis 201 57 f 9 creat requir pediatr studi intend encourag inclus comprehens label pediatr use permit use adult data establish pediatr efficaci specif rule allow pediatr use statement base adequ well control studi adult addit inform exist show cours diseas effect drug suffici similar adult pediatr patient permit extrapol adult efficaci data pediatr popul fda initi amend propos 201 57 f 9 iii indic fda determin whether effect drug suffici similar adult pediatr patient includ examin drug benefici advers effect fda also amend 201 57 f 9 iii make clear inform besid pharmacokinet data may necessari simpli establish applic adult data pediatr patient gener show drug use safe effect pediatr patient section 201 57 f 9 iii also modifi remov potenti misimpress uncontrol studi could demonstr effect 16 one comment question rule languag extrapol adult data pediatr patient comment said exact mechan mani psychiatr drug work known drug product extrapol adult pediatr popul may inaccur potenti hazard comment note random control studi tricycl antidepress pediatr patient rais question regard efficaci safeti issu rais base noncontrol data indic potenti risk might clear base adult data sudden cardiac death pediatr patient use tricycl fda agre extrapol adult experi inappropri thu unaccept case extrapol necessari rule altern conduct adequ well control studi pediatr patient case pediatr use statement base primarili adequ well control studi adult addit inform support pediatr use usual need ordinarili includ data pharmacokinet drug pediatr popul determin pediatr dosag inform data pharmacodynam studi drug pediatr patient data studi support safeti effect drug pediatr patient pertin premarket postmarket studi experi may necessari show drug use safe effect pediatr popul 17 one comment said preambl final regul clarifi inform support pediatr use propos 201 57 f 9 iii need limit data develop sponsor nda holder may includ data report studi academ research peer review journal prepar person relat nda sponsor agenc believ chang need revis 201 57 f 9 iv section suggest data must develop sponsor nda holder propos 201 57 f 9 iv fda receiv comment provis renumb 201 57 f 9 v final without chang e propos 201 57 f 9 v propos 201 57 f 9 v renumb 201 57 f 9 vi provid part f requir find substanti evid support pediatr indic pediatr use statement met pediatr popul subsect label shall contain follow statement safeti effect children establish 18 one comment express concern provis may creat disincent sponsor develop better inform pediatr use drug comment suggest fda requir mandatori phase safeti test appropri clinic studi pharmaceut pediatr popul altern comment recommend fda manufactur work develop agreement wherebi manufactur consent carri addit postapprov pediatr studi fda believ comment suggest action beyond scope rule fda encourag pediatr test discuss comment 4 section iii c document author requir pediatr studi case fda requir pediatr studi approv continu market rule howev add new requir pediatr studi rather describ kind data use support label claim f propos 201 57 f 9 vi propos 201 57 f 9 vi renumb 201 57 f 9 vii provid f sponsor believ none statement describ paragraph f 9 f 9 v renumb f 9 ii f 9 vi section appropri relev label particular drug sponsor shall provid reason omiss statement may propos altern statement fda may permit use altern statement 19 one comment assert propos adequ address problem larg number drug approv market year without pediatr usag inform label wide use pediatr patient substanti publish literatur regard pediatr use comment note propos 201 57 f 9 vi would impos sponsor respons provid inform would promot safe effect use prescript drug pediatr patient note sponsor may complex reason necessarili want includ pediatr inform label comment recommend final rule includ mechan would allow summari inform authorit publish literatur ad label current market drug inform would avail pediatr prescrib suggest rule provid option permit recogn authorit medic expert group expert provid inform support pediatr inform label lieu sponsor anoth comment urg agenc provid incorpor supplement indic drug label base sole inform submit person sponsor comment said chang made base studi report peer review medic literatur rather reli submiss sponsor comment state necessari make label certain drug particularli anticanc agent conform current state medic knowledg comment note fda restrict promot label use third parti payer often take posit agent label indic treatment cancer pediatr patient experiment therefor nonreimburs even though may safe effect sponsor primarili respons bring forth evid support label chang third parti could howev provid evid persuad agenc direct sponsor submit label supplement studi need conduct behalf sponsor order support label chang evid support label continu type qualiti would ordinarili support label statement publish literatur pediatr use may contribut evid authorit group may suggest approach view authorit group repres suffici evid effect respect comment concern reimburs agenc advis reimburs patient beyond scope rule fda author howev fda agre underli concern appropri indic label practition understand best prescrib drug patient medic benefit g propos 201 57 f 9 vii propos 201 57 f 9 vii renumb 201 57 f 9 viii state f drug product contain one excipi present increas risk toxic effect neonat pediatr subgroup special note risk gener contraind warn precaut section shall made 20 four comment express concern propos requir one comment said data relat toxic excipi includ preserv inconclus make requir inappropri comment state fda encourag collect analysi data enabl specif determin use excipi preserv anoth comment ask fda clarifi whether propos requir label contain statement excipi present increas risk advers effect neonat pediatr subgroup intend reflect publish literatur base studi design show whether increas risk exist ad clear determin increas risk would establish comment suggest final rule state sponsor reli exist inform requir conduct addit studi comment also suggest addit studi necessari anim data use rather requir clinic studi neonat suggest standard list could develop jointli industri fda third comment suggest requir label identifi increas risk toxic effect neonat pediatr group interpret establish requir sponsor conduct toxicolog studi identifi quantifi risk comment also state preambl final regul state whether increas risk toxic effect limit establish human data experi would also includ base anim vitro model fourth comment note anda holder may use excipi differ use refer list drug comment suggest anda holder requir provid specif inform regard excipi use final rule requir label drug product contain one inact ingredi present increas risk toxic effect neonat pediatr subgroup note risk contraind warn precaut section label toxic data inact ingredi exist inconclus revis 201 57 f 9 viii would requir label contain statement increas risk neonat pediatr subgroup howev case fda encourag applic collect analyz data inact ingredi preserv could repres pediatr risk data may includ human data anim data data deriv vitro model fda also note current regul alreadi requir anda applic whose inact ingredi differ use refer list drug identifi character inact ingredi propos drug product provid inform demonstr inact ingredi affect safeti propos drug product see 21 cfr 314 94 9 given provis reason believ inact ingredi use gener drug product less safe refer list drug agenc determin purpos final rule term excipi inact ingredi mean howev agenc gener use term inact ingredi agenc initi amend propos 201 57 f 9 vii refer inact ingredi instead excipi v legal author fda revis pediatr use subsect prescript drug label author feder food drug cosmet act act public health servic act ph act section 502 act prohibit fals mislead label drug includ section 201 n act failur reveal materi fact relat potenti consequ customari condit use section 502 f act requir drug label adequ direct use adequ warn use pediatr popul use may danger health well adequ warn unsaf dosag method durat administr necessari protect user section 502 j act prohibit use drug danger health use manner suggest label drug product meet requir paragraph section 502 act deem misbrand addit misbrand provis premarket approv provis act author fda requir prescript drug label provid practition adequ inform permit safe effect use drug product section 505 act fda approv nda drug shown safe effect intend use condit set forth drug label section 701 act 21 u c 371 author fda issu regul effici enforc act 201 100 21 cfr 201 100 fda label regul prescript drug product must bear label contain adequ inform licens practition use drug safe intend use section 201 57 describ specif categori inform includ inform drug use select subgroup gener popul must present meet requir 201 100 addit 21 cfr 314 125 fda approv nda unless among thing adequ safeti effect inform label use product label compli requir part 201 21 cfr part 201 section 351 ph act provid legal author agenc regul label shipment biolog product licens biolog product issu upon show meet standard design insur continu safeti puriti potenc product prescrib regul 42 u c 262 potenc biolog product includ effect 21 cfr 600 3 section 351 b ph act prohibit fals label biolog product fda regul part 201 appli prescript drug product includ biolog product drug product complianc 201 57 f 9 would consid misbrand unapprov new drug act noncompli product biolog product would addit consid fals label unlicens biolog product ph act vi implement primari purpos propos rule revis exist pediatr label requir expand basi inform use drug pediatr popul may includ propos rule would requir sponsor compli pediatr use provis 1 year date public final rule feder regist 21 sever comment said propos 1 year implement period short comment claim extrapol review data would time consum agenc would unabl approv pediatr use label within 1 year comment suggest agenc cooper industri establish 3year implement schedul requir sponsor submit revis label 1 year make rule effect 2 year agenc care consid comment revis implement schedul final rule agenc accept pediatr use inform base revis 201 57 f 9 januari 12 1995 sponsor continu oblig maintain label truth comprehens accord 201 57 includ 201 57 f 9 section 201 57 f 9 requir label contain least one statement 201 57 f 9 ii f 9 vi propos altern statement 201 57 f 9 vii statement must accur describ avail data sponsor must therefor reexamin exist data determin whether pediatr use subsect label modifi base adequ well control studi adult inform support pediatr use appropri submit supplement applic compli new 201 57 f 9 iv decemb 13 1996 sponsor believ diseas drug effect similar pediatr adult popul believ use pediatr patient otherwis adequ support data propos revis label new 201 57 f 9 iv need inform agenc conclus therefor fda expect sponsor examin avail inform updat pediatr label product appropri sponsor also examin data extent natur use product pediatr patient fda conclud particular drug wide use repres safeti hazard therapeut import pediatr popul drug sponsor submit pediatr use inform agenc may requir sponsor develop submit pediatr use inform fda made specif request submiss pediatr use inform expect identifi pediatr use sponsor fail provid inform agenc may consid product misbrand drug section 502 act fals label biolog product section 351 ph act well unapprov new drug unlicens biolog product see 21 u c 355 42 u c 262 final rule new revis pediatr indic statement pediatr indic statement pediatr use provis 201 57 f 9 ii f 9 iv would requir fda approv supplement applic accord 314 70 b 601 12 chang propos 201 57 f 9 ii f 9 iv add strengthen precaut contraind warn advers reaction add strengthen dosag administr instruct increas product safeti product biolog product could put effect time supplement cover chang submit fda accord 314 70 c minor editori chang product biolog product may made accord 314 70 compli rule refer children pediatr use subsect insert label product alreadi market must chang appropri pediatr popul pediatr patient agenc advis januari 12 1995 chang must made later first time label sent printer order reprint replenish old stock label chang product biolog product consid minor editori chang may submit annual report accord 314 70 new revis statement 201 57 f 9 viii regard inact ingredi may toxic neonat pediatr subgroup made accord provis 314 70 c 601 12 21 cfr 601 12 appropri supplement contain pediatr use inform mail cover plainli mark pediatr supplement product subject section 351 ph act label chang made accord 601 12 person question regard chang need guidanc whether supplement necessari contact one follow three divis appropri offic therapeut research review divis applic review polici hfm585 3015945109 offic vaccin research review divis vaccin relat product applic hfm475 3015942090 offic blood research review divis blood applic hfm370 3015942012 follow address center biolog evalu research food drug administr 1401 rockvil pike suit 200n rockvil md 20852 22 one comment suggest rule would substanti econom impact particularli agenc adher propos 1 year implement period comment said cost factor aris extens resourc requir reevalu avail clinic studi data literatur extrapol adult safeti data pediatr age group group comment note drug studi pediatr patient addit cost experienc adult popul may case requir inpati studi comment also claim encourag pediatr studi prior approv phase 4 commit could lengthen develop process slow drug approv therebi addit econom impact agenc consid comment revis implement schedul final rule implement schedul discuss section vi document agenc stress rule requir sponsor conduct pediatr studi author requir studi found act regul alreadi promulg rather rule recogn altern method establish substanti evid support pediatr label claim find substanti evid support pediatr indic pediatr use statement met specif subgroup pediatr popul sponsor must instead indic data avail sponsor believ pediatr use statement would inappropri irrelev label particular drug must provid reason omit statement rule affect determin agenc pediatr studi need approv new drug vii environment impact agenc determin 21 cfr 25 24 8 action type individu cumul signific effect human environ therefor neither environment assess environment impact statement requir viii analysi impact fda examin impact final rule execut order 12866 regulatori flexibl act pub l 96354 execut order 12866 direct agenc assess cost benefit avail regulatori altern regul necessari select regulatori approach maxim net benefit includ potenti econom environment public health safeti advantag distribut impact equiti agenc believ final rule consist principl set execut order addit final rule signific regulatori action defin execut order regulatori flexibl act requir agenc analyz regulatori option would minim signific impact rule small entiti final rule impos addit requir sponsor conduct pediatr studi agenc certifi final rule signific econom impact substanti number small entiti therefor regulatori flexibl act analysi requir list subject 21 cfr part 201 drug label report recordkeep requir therefor feder food drug cosmet act public health servic act author deleg commission food drug 21 cfr part 201 amend follow part 201_label 1 author citat 21 cfr part 201 continu read follow author sec 201 301 501 502 503 505 506 507 508 510 512 530542 701 704 721 feder food drug cosmet act 21 u c 321 331 351 352 353 355 356 357 358 360 360b 360gg360ss 371 374 379e sec 215 301 351 361 public health servic act 42 u c 216 241 262 264 2 section 201 57 amend revis paragraph f 9 read follow 201 57 specif requir content format label human prescript drug f 9 pediatr use pediatr popul pediatr patient purpos paragraph f 9 ii f 9 viii setion term pediatr popul pediatr patient defin pediatr age group birth 16 year includ age group often call neonat infant children adolesc ii specif pediatr indic e indic differ approv adult support adequ well control studi pediatr popul shall describ indic usag section label appropri pediatr dosag inform shall given dosag administr section label pediatr use subsect shall cite limit pediatr indic need specif monitor specif hazard associ use drug subset pediatr popul e g neonat differ pediatr adult respons drug inform relat safe effect pediatr use drug data summar subsect label discuss detail appropri clinic pharmacolog clinic studi section appropri inform shall also contain contraind warn elsewher precaut section iii specif statement pediatr use drug indic also approv adult base adequ well control studi pediatr popul shall summar pediatr use subsect label discuss detail appropri clinic pharmacolog clinic studi section appropri pediatr dosag shall given dosag administr section label pediatr use subsect label shall also cite limit pediatr use statement need specif monitor specif hazard associ use drug subset pediatr popul e g neonat differ pediatr adult respons drug inform relat safe effect pediatr use drug appropri inform shall also contain contraind warn elsewher precaut section iv fda may approv drug pediatr use base adequ well control studi adult inform support pediatr use case agenc conclud cours diseas effect drug benefici advers suffici similar pediatr adult popul permit extrapol adult efficaci data pediatr patient addit inform support pediatr use must ordinarili includ data pharmacokinet drug pediatr popul determin appropri dosag inform data pharmacodynam studi drug pediatr popul data studi support safeti effect drug pediatr patient pertin premarket postmarket studi experi may necessari show drug use safe effect pediatr patient drug approv pediatr use base adequ well control studi adult inform support pediatr use pediatr use subsect label shall contain either follow statement reason altern safeti effect drug name establish age group _ _ note limit e g data pediatr patient 2 applic certain indic approv adult use drug name age group support evid adequ well control studi drug name adult addit data insert word accur describ data submit support find substanti evid effect pediatr popul data summar preced prescrib statement subsect label shall discuss detail appropri clinic pharmacolog clinic studi section exampl pediatr pharmacokinet pharmacodynam studi dose respons inform describ clinic pharmacolog section pediatr dose instruct shall includ dosag administr section label differ pediatr adult respons need specif monitor dose adjust inform relat safe effect use drug pediatr patient shall cite briefli pediatr use subsect appropri contraind warn precaut dosag administr section v requir find substanti evid support pediatr indic pediatr use statement met particular pediatr popul pediatr use subsect label shall contain appropri statement safeti effect pediatr patient age _ establish use drug pediatr popul associ specif hazard hazard shall describ subsect label appropri hazard shall state contraind warn section label subsect shall refer vi requir find substanti evid support pediatr indic pediatr use statement met pediatr popul subsect label shall contain follow statement safeti effect pediatr patient establish use drug prematur neonat infant pediatr subgroup associ specif hazard hazard shall describ subsect label appropri hazard shall state contraind warn section label subsect shall refer vii sponsor believ none statement describ paragraph f 9 ii f 9 vi section appropri relev label particular drug sponsor shall provid reason omiss statement may propos altern statement fda may permit use altern statement fda determin statement describ paragraph appropri relev drug label altern statement accur appropri viii drug product contain one inact ingredi present increas risk toxic effect neonat pediatr subgroup special note risk shall made gener contraind warn precaut section date novemb 15 1994 supplem signer david kessler signer signjob commission food drug signjob frfile fr doc 9430238 file 121294 8 45 frfile bill bill code 416001f bill